Mach7 Technologies reported in-line FY22 earnings with Morgans expectations with 42% growth in revenues on FY21.

The trend to more SaaS deals is viewed positively by the analyst and management guided to double digit growth in revenue in FY23 and sales orders growing to $36m from $30m in FY22.

There are no changes to Morgans earnings forecasts.

The target is maintained at $1.34 and the rating remains ADD.

Sector: Health Care Equipment & Services.

Target price is $1.34.Current Price is $0.71. Difference: $0.63 - (brackets indicate current price is over target). If M7T meets the Morgans target it will return approximately 47% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena